ADC reports Phase I data for ADCT-301 in Hodgkin's lymphoma

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 35 evaluable patients with Hodgkin's lymphoma in a Phase I trial

Read the full 206 word article

User Sign In